R Ceravolo

Summary

Affiliation: University of Pisa
Country: Italy

Publications

  1. ncbi request reprint Orthostatic hypotension in de novo Parkinson disease
    Ubaldo Bonuccelli
    Department of Neuroscience, Section of Neurology, Movement Disorders Unit, University of Pisa, Pisa, Italy
    Arch Neurol 60:1400-4. 2003
  2. ncbi request reprint Assessing neuroprotection in Parkinson's disease: from the animal models to molecular neuroimaging in vivo
    R Ceravolo
    Department of Neuroscience, University of Pisa, Pisa, Italy
    J Neural Transm Suppl . 2006
  3. pmc Dopamine Transporter SPECT Imaging in Corticobasal Syndrome
    Roberto Cilia
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    PLoS ONE 6:e18301. 2011
  4. doi request reprint Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: a SPECT follow-up study
    Roberto Ceravolo
    Department of Neuroscience, University of Pisa, Via Roma, 67, 56126 Pisa, Italy
    Parkinsonism Relat Disord 19:557-9. 2013
  5. ncbi request reprint Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease
    Roberto Ceravolo
    Department of Neuroscience, University of Pisa, Italy
    Clin Neuropharmacol 27:166-70. 2004
  6. ncbi request reprint Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers
    R Ceravolo
    Department of Neurosciences, University of Pisa, Italy
    Neurology 65:1971-3. 2005
  7. doi request reprint Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study
    C Rossi
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Eur J Neurol 17:626-30. 2010
  8. doi request reprint Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders
    Roberto Ceravolo
    Department of Neurosciences, University of Pisa, Pisa, Italy
    J Neurol 257:S276-83. 2010
  9. doi request reprint Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management
    Roberto Ceravolo
    Department of Neurosciences, University of Pisa, Pisa, Italy
    Parkinsonism Relat Disord 15:S111-5. 2009
  10. ncbi request reprint Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study
    R Ceravolo
    Department of Neuroscience, University of Pisa, Italy
    J Neural Transm (Vienna) 111:1065-73. 2004

Collaborators

Detail Information

Publications49

  1. ncbi request reprint Orthostatic hypotension in de novo Parkinson disease
    Ubaldo Bonuccelli
    Department of Neuroscience, Section of Neurology, Movement Disorders Unit, University of Pisa, Pisa, Italy
    Arch Neurol 60:1400-4. 2003
    ..It is accepted that orthostatic hypotension is a clinical marker for the diagnosis of multiple system atrophy, but conflicting data indicate that it may also be present in Parkinson disease (PD)...
  2. ncbi request reprint Assessing neuroprotection in Parkinson's disease: from the animal models to molecular neuroimaging in vivo
    R Ceravolo
    Department of Neuroscience, University of Pisa, Pisa, Italy
    J Neural Transm Suppl . 2006
    ....
  3. pmc Dopamine Transporter SPECT Imaging in Corticobasal Syndrome
    Roberto Cilia
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    PLoS ONE 6:e18301. 2011
    ..In addition, we assessed prevalence and features of individuals with CBS and in vivo evidence of preserved nigral neuronal density...
  4. doi request reprint Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: a SPECT follow-up study
    Roberto Ceravolo
    Department of Neuroscience, University of Pisa, Via Roma, 67, 56126 Pisa, Italy
    Parkinsonism Relat Disord 19:557-9. 2013
    ..To demonstrate that degeneration of substantia nigra neurons may occur at later stages of disease in some patients with corticobasal syndrome (CBS) who evidenced preserved nigrostriatal pathway at a baseline FP-CIT SPECT study...
  5. ncbi request reprint Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease
    Roberto Ceravolo
    Department of Neuroscience, University of Pisa, Italy
    Clin Neuropharmacol 27:166-70. 2004
    ..These data suggest that cognitive or behavioral benefits after ChE inhibitor therapy are related to a clear increase of rCBF in crucial areas specifically involved in the attentional and limbic networks...
  6. ncbi request reprint Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers
    R Ceravolo
    Department of Neurosciences, University of Pisa, Italy
    Neurology 65:1971-3. 2005
    ..They found evidence of preserved presynaptic nigrostriatal function, suggesting that parkinsonism in the X fragile premutation might be related to postsynaptic dopaminergic changes or different neurotransmitter alterations...
  7. doi request reprint Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study
    C Rossi
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Eur J Neurol 17:626-30. 2010
    ..TD patients are characterized by a slower disease progression and a minor cognitive impairment. Striatal density of DAT, as quantified by FP-CIT SPECT, has been reported to correlate with rigidity and akinesia but not with tremor...
  8. doi request reprint Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders
    Roberto Ceravolo
    Department of Neurosciences, University of Pisa, Pisa, Italy
    J Neurol 257:S276-83. 2010
    ..Hypomanic and psychotic episodes are best managed with a reduction of DRT performed in hospital also by using atypical antipsychotics low dose...
  9. doi request reprint Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management
    Roberto Ceravolo
    Department of Neurosciences, University of Pisa, Pisa, Italy
    Parkinsonism Relat Disord 15:S111-5. 2009
    ..There is no empirical evidence supporting the use of psychiatric drugs for ICDs in PD. Functional neuroimaging studies such as functional MRI and PET can investigate in vivo the neurobiological basis of these pathological behaviours...
  10. ncbi request reprint Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study
    R Ceravolo
    Department of Neuroscience, University of Pisa, Italy
    J Neural Transm (Vienna) 111:1065-73. 2004
    ....
  11. ncbi request reprint Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia
    R Ceravolo
    Department of Neuroscience, Neurology Section, University of Pisa, Pisa, Italy
    J Neural Transm (Vienna) 113:1787-90. 2006
    ....
  12. ncbi request reprint Paroxetine in Parkinson's disease: effects on motor and depressive symptoms
    R Ceravolo
    Department of Neuroscience, University of Pisa, Italy
    Neurology 55:1216-8. 2000
    ..Depression, as evaluated by Beck Depression Inventory and Hamilton Depression Rating Scale, improved from baseline to final visit (p < 0.05 by analysis of variance)...
  13. ncbi request reprint Lack of association between mtDNA haplogroups and Alzheimer's disease in Tuscany
    M Mancuso
    Department of Neuroscience, Neurological Clinic, University of Pisa, Via Roma 67, I 56126, Pisa, Italy
    Neurol Sci 28:142-7. 2007
    ..Further studies will be required to define the contribution of mtDNA haplogroups, if any, to the pathogenesis of AD. A correct population selection, in order to minimise the risk of genetic contamination, is essential in these studies...
  14. ncbi request reprint Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease
    R Ceravolo
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Neurol Sci 24:162-3. 2003
    ..001) occipital hypoperfusion with respect to AD was reported. Our findings confirm that dopaminergic nigrostriatal function is impaired in LBD. The selective occipital hypoperfusion in LBD needs to be further investigated...
  15. ncbi request reprint From mild cognitive impairment to dementia: a prevalence study in a district of Tuscany, Italy
    G Tognoni
    Department of Neuroscience, Clinical Neurology, University of Pisa, Pisa, Italy
    Acta Neurol Scand 112:65-71. 2005
    ..Identification of cases with mild cognitive impairment (MCI) was given high priority, because this condition has been suggested as a term for the boundary area between normal aging and dementia...
  16. ncbi request reprint Psychiatric comorbidity in a population of Parkinson's disease patients
    A Nuti
    Department of Neuroscience, Neurology Section, University of Pisa, Pisa, Italy
    Eur J Neurol 11:315-20. 2004
    ....
  17. ncbi request reprint No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease
    D Micheli
    Department of Neuroscience, Neurological Clinic, University of Pisa, Italy
    J Alzheimers Dis 10:371-8. 2006
    ..These results suggest that the serotoninergic system may be not involved in the pathogenesis of depressive symptoms in AD patients, and it may be involved in other aspects of disease pathophysiology like cognitive symptoms and psychosis...
  18. doi request reprint The relationship between cerebral vascular disease and parkinsonism: The VADO study
    A Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Parkinsonism Relat Disord 18:775-80. 2012
    ..However the status of striatal dopamine transporter (DAT) and the effects of brain vascular lesions on motor features and levodopa responsiveness are poorly defined...
  19. doi request reprint Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in parkinsonian patients
    R Ceravolo
    Clinica Neurologica, Dipartimento di Neuroscienze, Universita di Pisa, Pisa, Italy
    Eur J Neurol 18:842-9. 2011
    ..To evaluate the effects of 25-Hz deep brain stimulation of the nucleus tegmenti pedunculopontini (PPTg) on brain metabolic activity...
  20. doi request reprint CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease
    R Ceravolo
    Department of Neuroscience, University of Pisa, Via Roma 67, 56126 Pisa, Italy
    Brain Res Bull 76:80-4. 2008
    ..These results indicate the existence of a correlation between impairment of cerebral metabolism, estimated throughout FDG-PET, and CSF Tau protein levels...
  21. doi request reprint The PRIAMO study: background, methods and recruitment
    Angelo Antonini
    Parkinson Institute, Milan, Italy
    Neurol Sci 29:61-5. 2008
    ..PRIAMO has analysed a total of 1307 patients (out of 1325 initially enrolled). We expect that PRIAMO will substantially help to quantify the burden of NMS in patients with parkinsonism...
  22. doi request reprint Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction
    R Ceravolo
    Neurology Unit, Department of Neuroscience, University of Pisa, Pisa, Italy
    Eur J Neurol 20:480-5. 2013
    ..However, the potential interference of psychoactive as well as anti-parkinsonian drugs on DAT density should be taken into account...
  23. ncbi request reprint Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): association studies with psychosis in Alzheimer disease
    A Rocchi
    Department of Neuroscience Neurological Clinics, University of Pisa, Pisa, Italy
    Genet Test 7:309-14. 2003
    ..On the contrary, the serotonin transporter does not appear to be a major susceptibility factor in the pathophysiology of the disease...
  24. ncbi request reprint Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement
    Claudio Lucetti
    Department of Neuroscience, University of Pisa, Italy
    Parkinsonism Relat Disord 12:279-83. 2006
    ..To evaluate in a prospective longitudinal study the evolution of functional disability and the response to dopaminergic therapy in PD patients with and without autonomic involvement...
  25. pmc Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports
    G Siciliano
    Department of Neurosciences, Neurology Clinic, University of Pisa, Via Roma 67, 56126 Pisa, Italy
    J Neurol Neurosurg Psychiatry 71:685-7. 2001
    ....
  26. ncbi request reprint The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects
    A Rocchi
    Department of Neuroscience, Neurological Clinic, University of Pisa, Italy
    Curr Alzheimer Res 6:224-37. 2009
    ....
  27. ncbi request reprint SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study
    R Ceravolo
    Department of Neuroscience, Clinical Neurology, and Department of Psychiatry, University of Pisa, Italy
    Clin Neuropharmacol 24:221-7. 2001
    ..05 according to an analysis of variance). Our findings suggest that SSRIs do not significantly worsen extrapyramidal symptomatology and may ameliorate depression in patients with PD...
  28. doi request reprint Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease
    S Mazzucchi
    Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
    Acta Neurol Scand 131:191-5. 2015
    ..Serotonergic system is believed to play a role in levodopa-induced-dyskinesias pathogenesis, and serotonin transporter has been evaluated as potential target...
  29. doi request reprint Mesolimbic dopaminergic dysfunction in Parkinson's disease depression: evidence from a 123I-FP-CIT SPECT investigation
    D Frosini
    Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67 56126, Pisa, Italy
    J Neural Transm (Vienna) 122:1143-7. 2015
    ..336, p < 0.05). Our data indicate a significant association between PD depression and cingulate dopaminergic denervation supporting the dopaminergic hypothesis of PD depression...
  30. ncbi request reprint Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging
    M Cosottini
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Acta Neurol Scand 116:37-42. 2007
    ....
  31. ncbi request reprint The safety of dopamine agonists in the treatment of Parkinson's disease
    Ubaldo Bonuccelli
    University of Pisa, Department of Neuroscience, Via Roma, 67 56100 Pisa, Italy
    Expert Opin Drug Saf 7:111-27. 2008
    ..This review focuses on the potential negative effects related to the use of dopamine agonists in the treatment of Parkinson's disease...
  32. ncbi request reprint 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease
    Roberto Ceravolo
    MRC Cyclotron Unit, Hammersmith Hospital, Institute of Neurology, London, UK
    Synapse 43:201-7. 2002
    ..0059 +/- 0.0028) in the absence of this drug. These findings are compatible with clinical doses of tolcapone having a significant blocking effect on peripheral and central COMT but not DDC activity in PD...
  33. doi request reprint The hOGG1 Ser326Cys polymorphism is not associated with sporadic Parkinson's disease
    Fabio Coppede
    Department of Neuroscience, Neurological Clinic, University of Pisa, Via Roma 67, 56126 Pisa, Italy
    Neurosci Lett 473:248-51. 2010
    ..Moreover, the hOGG1 Ser326Cys polymorphism was not associated with disease age at onset (p=0.791). Overall, present results suggest that the hOGG1 Ser326Cys polymorphism is not associated with sporadic PD...
  34. doi request reprint The hOGG1 Ser326Cys polymorphism and Huntington's disease
    Fabio Coppede
    Department of Neuroscience, Neurological Clinic, University of Pisa, Via Roma 67, 56126 Pisa, Italy
    Toxicology 278:199-203. 2010
    ..041) earlier disease onset than Ser326Ser wild-type individuals, suggesting a possible role of the hOGG1 Ser326Cys polymorphism in HD phenotype...
  35. ncbi request reprint Antipsychotic drugs in Huntington's disease
    E Unti
    a Department of Clinical and Experimental Medicine Neurology Unit, University of Pisa, Pisa, Italy
    Expert Rev Neurother . 2016
    ..Despite a large number of case reports, randomized controlled trials (RCT) and drug comparison studies are lacking...
  36. doi request reprint Current treatment and future prospects of dopa-induced dyskinesias
    S Mazzucchi
    Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
    Drugs Today (Barc) 51:315-29. 2015
    ....
  37. doi request reprint "Parkinson-dementia" diseases: a comparison by double tracer SPECT studies
    Carlo Rossi
    Department of Neuroscience, Neurology Section, University of Pisa, Pisa, Italy
    Parkinsonism Relat Disord 15:762-6. 2009
    ..Finally no correlation was found between any regional perfusional changes and nigro-striatal dysfunction. We conclude that neither studies with 123I-FP-CIT nor ECD/SPECT were able to discriminate between DLB and PDD in vivo...
  38. doi request reprint Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype
    Michelangelo Mancuso
    Department of Neuroscience, Neurological Clinic, University of Pisa, Via Roma 67, 56126 Pisa, Italy
    Neurosci Lett 444:83-6. 2008
    ..No significant difference was observed between different haplogroups and haplogroup clusters in the cognitive or motor progression of the disease. Our study does not support any association between mtDNA haplogroups and HD...
  39. ncbi request reprint Contribution of cerebellum and brainstem in the control of eye movement: evidence from a functional study in a clinical model
    R Ceravolo
    Department of Neuroscience, Neurology Section, University of Pisa, Pisa, Italy
    Acta Neurol Scand 105:32-9. 2002
    ....
  40. ncbi request reprint Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease
    Michelangelo Mancuso
    Department of Neurosciences, Neurological Clinics, University of Pisa, Via Roma 67, 56126, Pisa, Italy
    Exp Neurol 182:421-6. 2003
    ..These results support the hypothesis of a systemic impairment of the mitochondrial function in AD and indicate that decreased COX activity could have functional consequences on metabolism...
  41. ncbi request reprint Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes
    Lorenzo Kiferle
    Department of Neuroscience, University of Pisa, Via Roma 67, 56127 Pisa, Italy
    Neurosci Lett 422:228-31. 2007
    ..These data might suggest that 5-HTTLPR and 5-HT2A polymorphisms are not major susceptibility factors of psychotic symptoms in PD patients...
  42. ncbi request reprint Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study
    Claudio Lucetti
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Mov Disord 22:2170-5. 2007
    ..05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex...
  43. doi request reprint Predictive value of nigrostriatal dysfunction in isolated tremor: a clinical and SPECT study
    Roberto Ceravolo
    Department of Neurosciences, Neurologic Clinic, University of Pisa, Pisa, Italy
    Mov Disord 23:2049-54. 2008
    ..We suggest this disorder to be labeled as "isolated tremor with dopaminergic presynaptic dysfunction"...
  44. ncbi request reprint Association between amantadine and the onset of dementia in Parkinson's disease
    Rivka Inzelberg
    Department of Neurology, Hillel Yaffe Medical Center, Hadera, Israel
    Mov Disord 21:1375-9. 2006
    ..01). Age of PD onset also significantly influenced the duration of PD until dementia. Amantadine use may delay the onset of dementia in PD patients and may attenuate its severity...
  45. ncbi request reprint The mtDNA A8344G "MERRF" mutation is not a common cause of sporadic Parkinson disease in Italian population
    Michelangelo Mancuso
    Parkinsonism Relat Disord 14:381-2. 2008
  46. ncbi request reprint Pulse pressure and endothelial dysfunction in never-treated hypertensive patients
    Roberto Ceravolo
    Internal Medicine and Cardiovascular Diseases Unit, Department of Experimental and Clinical Medicine G Salvatore, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy
    J Am Coll Cardiol 41:1753-8. 2003
    ..This study sought to investigate whether pulse pressure (PP) is associated with endothelium-dependent vasodilation in a group of never-treated hypertensives...
  47. ncbi request reprint [Mechanism of troponin and CK-MB release after percutaneous coronary interventions]
    Annalisa Mongiardo
    U O di Cardiologia Interventistica, Universita degli Studi Magna Graecia, Catanzaro
    Ital Heart J Suppl 3:270-4. 2002
    ..In conclusion, after successful percutaneous coronary interventions, minor elevation of troponin may occur. In this setting cardiac troponin I is a highly specific marker of myocardial injury...
  48. ncbi request reprint Protection of human endothelial cells from oxidative stress: role of Ras-ERK1/2 signaling
    Giovanni Cuda
    Dipartimento di Medicina Sperimentale e Clinica G Salvatore, Università di Catanzaro Magna Graecia, Napoli, Italy
    Circulation 105:968-74. 2002
    ..Moreover, ERK1/2 signaling has been involved in both protection and induction of apoptosis...
  49. ncbi request reprint Association of LDL cholesterol with carotid atherosclerosis in menopausal women affected by the metabolic syndrome
    Tiziana Montalcini
    Department of Clinical and Experimental Medicine G Salvatore, University of Catanzaro Magna Graecia, Via T Campanella, 88100 Catanzaro, Italy
    Nutr Metab Cardiovasc Dis 15:368-72. 2005
    ..The metabolic syndrome is a highly prevalent condition associated with cardiovascular disease. However, the contribution of LDL to cardiovascular risk is not estimated since it is not part of ATP III criteria...